Merck KGaA spotlights need for deals to shake up R&D, with external partners key to new drugs
German healthcare company Merck KGaA wants to ramp up its R&D productivity with the goal of launching a new drug, or tacking on a new indication to an approved med, every one and a half years. To get there, the life sciences and health tech company will beef up its external work through in-licensing and strategic partnerships.
The more than three-century-old company outlined a future in which more than half of its new launches will come from external innovators and the pipeline roadmap will focus on oncology, neurology and immunology. As of now, the company’s therapeutics pipeline consists of four externally-derived molecules and nine in-house ones, according to an update this month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.